United Health Products Inc (OTC: UEEC) is a medical device company developing CelluSTAT, a patented hemostatic gauze designed to absorb exudate and control bleeding from superficial wounds. The company has generated $0 in revenue for the fiscal years ended December 31, 2025 and December 31, 2024, funding operations entirely through debt and equity financings. CelluSTAT is made from cotton and is currently cleared for superficial wound care use; the company is pursuing U.S. FDA Class III Premarket Approval and CE Mark certification in Europe to enter the surgical market. As of the 10-K filed April 15, 2026, the company operates at a working capital deficit, carries convertible notes payable including a $289,267 senior convertible note from Alumni Capital LP entered December 16, 2025, and has an accumulated stockholders' deficit. No audit committee exists; board of directors performs that function. The company is incorporated in Nevada and headquartered at 520 Fellowship Road, Mount Laurel, New Jersey.

Revenue model

No revenue as of FY2025 and FY2024 (both periods: $0 reported). Operations are funded through sales of common stock, convertible notes payable, and related-party financing. The intended revenue model upon regulatory approval is product sales of CelluSTAT hemostatic gauze into healthcare and surgical markets.

Products and services

CelluSTAT: a patented cotton-based hemostatic gauze for superficial wound care and hemostasis. The company is pursuing FDA Class III Premarket Approval (PMA) and CE Mark certification for use in human surgical applications. As of the filing date, CelluSTAT has not received PMA approval and the company received an FDA Warning Letter, the resolution timeline of which is uncertain.

Customers and end markets

Target end markets are healthcare settings including surgical facilities, based on company disclosures in the 10-K filed April 15, 2026. No commercial customers exist as of FY2025 given $0 revenues.

Value-chain role

Pre-revenue medical device developer and manufacturer. The company develops and intends to manufacture and market CelluSTAT directly. It is exploring collaboration arrangements where a corporate partner could serve as substitute Sponsor of a CelluSTAT clinical study, with United Health Products retaining exclusive Rights to Reference study data for its own PMA application.

Geographic exposure

Primary regulatory focus is the United States (FDA PMA) and Europe (CE Mark), per 10-K filed April 15, 2026. Headquarters: 520 Fellowship Road, Mount Laurel, New Jersey.

Source: SEC 10-K, filed 2026-04-15

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Xtant Medical Holdings Inc Axe Compute Inc Rxsight Inc Sanara Medtech Inc OraSure Technologies Inc Retractable Technologies Inc VolitionRX Ltd PROJECT SAGE OLDCO, INC. TELA Bio Inc